#Canada #Toronto #AmacaThera #AmacaGel #Eyal Ron

Dr. Eyal S. Ron Joins AmacaThera Board to Drive Strategic Growth

AmacaThera, a pioneering clinical-stage biotechnology firm, has made a significant announcement regarding the addition of Dr. Eyal S. Ron to its board of directors. This strategic move is aimed at steering the company toward innovative solutions in the field of long-acting therapies, particularly for pain management post-surgery.

On January 8, 2025, AmacaThera revealed that Dr. Ron, an experienced entrepreneur and life sciences strategist with over three decades in the sector, will lend his expertise to the company. His track record in growing health solutions has positioned him as a key figure in developing products that meet strategic global partnerships and clinical pipeline progress.

Dr. Ron expressed his enthusiasm about joining the AmacaThera team during a pivotal time in its journey. He has been collaborating closely with the executive team and looks forward to making impactful contributions, especially to the phase 2 clinical trials of their lead product, AMT-143, aimed at addressing postoperative pain. Moreover, he is eager to assist in advancing other groundbreaking therapies that arise from AmacaThera's proprietary platform, AmacaGel™. This unique hydrogel technology holds potential for significantly improving drug delivery across various therapeutic indications.

The CEO of AmacaThera, Dr. Mike Cooke, remarked on Dr. Ron's unmatched scientific expertise and effective business leadership experience. Dr. Ron's ability to facilitate innovation and build strategic partnerships is anticipated to be a crucial asset that will aid in achieving the company's strategic objectives and accelerating the development of transformative treatments.

About AmacaThera

AmacaThera focuses on maintaining a clinical-stage biotechnology profile, concentrating specifically on hydrogel formulations that prolong the release of therapeutic agents. Their leading platform, AmacaGel™, is engineered to deliver long-lasting treatments with improved patient outcomes while minimizing systemic side effects.

Currently, AmacaThera’s flagship product, AMT-143, is transitioning into phase 2 clinical trials and has already demonstrated exceptional pharmacokinetics, positioning it as a promising alternative to opioid-based solutions for postoperative pain management. The AmacaGel™ platform employs a physical gelation hydrogel composed of two well-established polymers. Designed to liquefy under shear stress, it can seamlessly be administered through a standard syringe and forms a deposit quickly upon body temperature activation.

In its efforts to drive innovation, AmacaThera is heavily invested in key therapeutic areas, including pain management and oncology. The company boasts a robust support system from prominent investors such as Lumira Ventures, BDC Capital, StandUp Ventures, MaRS IAF, and Changrong Capital, all of which ensure a strong foundation for future growth and development.

The appointment of Dr. Eyal S. Ron to AmacaThera's board symbolizes a commitment to leading-edge research and development in the biotechnology sphere, encouraging advancements that prioritize patient needs on a global scale. As AmacaThera continues to evolve, the incorporation of Dr. Ron's insights will play a substantial role in navigating the landscape of innovative healthcare solutions effectively.

For more information on AmacaThera and their groundbreaking work, visit AmacaThera's official website.